Starling Oncology Institute, Inc. Common Stock
STLN
39 hedge funds and large institutions have $108M invested in Starling Oncology Institute, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 23 increasing their positions, 8 reducing their positions, and 2 closing their positions.
188% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 8
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
8% more funds holding
Funds holding: 36 → 39 (+3)
2.5% more ownership
Funds ownership: 29.89% → 32.39% (+2.5%)
2% less capital invested
Capital invested by funds: $111M → $108M (-$2.53M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.54M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.67M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.62M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$655K |
| 5 |
State Street
Boston,
Massachusetts
|
+$526K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$899K |
| 2 |
Millennium Management
New York
|
-$613K |
| 3 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
-$301K |
| 4 |
DM
Deerfield Management
New York
|
-$136K |
| 5 |
SCM
Saba Capital Management
New York
|
-$113K |
STLN Hedge Fund Activity: Q3 2022 in Review
39 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Starling Oncology Institute, Inc. Common Stock (STLN) for Q3 2022, worth a combined $108M — down 2.3% from $111M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new STLN positions and 2 closed out — a net gain of 3 holders — while 23 added to existing stakes and 8 trimmed.
The largest buyer was BlackRock, adding an estimated $4.54M. The largest seller was Redmile Group, cutting an estimated $899K.
- 39 institutional investors held Starling Oncology Institute, Inc. Common Stock (STLN) as of Q3 2022, up from 36 in Q2 2022.
- Funds reported $108M of Starling Oncology Institute, Inc. Common Stock stock for Q3 2022, down 2.3% quarter-over-quarter.
- 5 funds opened new Starling Oncology Institute, Inc. Common Stock positions in Q3 2022 and 2 closed out, a net change of +3 holders.
- The largest Starling Oncology Institute, Inc. Common Stock buyer in Q3 2022 was BlackRock, an estimated $4.54M added.
- The largest Starling Oncology Institute, Inc. Common Stock seller in Q3 2022 was Redmile Group, an estimated $899K sold.
Based on aggregated 13F filings for Q3 2022.